ACE: Acarbose Cardiovascular Evaluation trial
|Dates:||2008 - 2022|
|Funding:||Bayer Schering Pharma|
|Collaborators:||Diabetes Trial Unit (DTU), University of Oxford; University of Beijing|
The ACE trial is being conducted in Hong Kong and China, and is investigating the effects of an oral anti-diabetes drug containing acarbose on preventing recurrent cardiovascular disease (CVD) and type 2 diabetes in individuals with CVD and pre-diabetes. The trial is recruiting approximately 7,500 individuals with CVD, who also have pre-diabetes. Trial results are expected in 2013.
HERC is conducting the economic analysis alongside the trial.